Michael J. LaBarre - Jul 18, 2023 Form 4 Insider Report for HALOZYME THERAPEUTICS, INC. (HALO)

Role
SVP, CHIEF TECHNICAL OFFICER
Signature
/s/ James R. Oehler, Attorney-in-Fact
Stock symbol
HALO
Transactions as of
Jul 18, 2023
Transactions value $
-$98,203
Form type
4
Date filed
7/19/2023, 04:10 PM
Previous filing
Jun 22, 2023
Next filing
Aug 23, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HALO Common Stock Options Exercise $184K +10K +7.05% $18.41 152K Jul 18, 2023 Direct F1
transaction HALO Common Stock Sale -$404K -10K -6.58% $40.43 142K Jul 18, 2023 Direct F1, F2
transaction HALO Common Stock Options Exercise $99.1K +7.18K +5.06% $13.81 149K Jul 18, 2023 Direct F3
transaction HALO Common Stock Options Exercise $22.9K +2.83K +1.89% $8.11* 152K Jul 18, 2023 Direct F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HALO Option to Purchase Common Stock Options Exercise $0 -10K -57.13% $0.00 7.51K Jul 18, 2023 Common Stock 10K $18.41 Direct F1, F5
transaction HALO Option to Purchase Common Stock Options Exercise $0 -7.18K -21.1% $0.00 26.8K Jul 18, 2023 Common Stock 7.18K $13.81 Direct F6
transaction HALO Option to Purchase Common Stock Options Exercise $0 -2.83K -3.6% $0.00 75.6K Jul 18, 2023 Common Stock 2.83K $8.11 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The option exercise and sale reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2 Represents a weighted average sales price per share. These shares were sold at prices ranging from $40.10 to $40.84. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3 Represents an acquisition of 7,175 shares by the Reporting Person pursuant to a cash exercise and hold transaction.
F4 Represents an acquisition of 2,825 shares by the Reporting Person pursuant to a cash exercise and hold transaction.
F5 This option was granted on February 14, 2018 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter.
F6 This option was granted on February 4, 2015 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter.
F7 This option was granted on February 3, 2016 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter.